MedAble has announced a collaboration with non-profit Every Cure for conducting global, remote clinical trials for drug repurposing candidates.

Every Cure was officially launched, in collaboration with the Clinton Global Initiative, in September to scale up a new ‘drug repurposing’ research approach for identifying rare disease treatments.

Under the partnership, Medable will provide specialised software and services for the international, remote clinical trials.

Medable CEO and co-founder Dr Michelle Longmire said: “We live in an era of exponential improvements in medicine, but traditional clinical trials are a bottleneck in the system, and only yield 50 new FDA-approved treatments per year.

“With new technologies and new research techniques, we believe it’s possible to drastically increase the number of therapies in development, and Every Cure will be an important leader in driving that change.”

Along with Medable, Every Cure will carry out clinical trials of high impact opportunities for the Food and Drug Administration’s (FDA) approval of an existing drug with a new indication.

Over 300 decentralised and hybrid clinical trials have used Medable’s software-as-a-service (SaaS) platform. These trials served over one million patients and research participants in 60 countries.

Every Cure aims to identify new uses for existing drugs and conduct clinical trials of promising treatments for assessing their effectiveness for obtaining FDA approval and/or off-label use clinically.

Every Cure co-founder Dr David Fajgenbaum said: “Every Cure is dedicated to unlocking all diseases that existing drugs can treat by developing a comprehensive open-source database of drug repurposing opportunities and launching clinical trials of the most promising treatments.”

In November last year, Medable unveiled a SaaS electronic consent management solution, Total Consent, for all decentralised and hybrid clinical trials in more than 120 locations worldwide.